Skip to content
Kreastel
Opening soon

trastuzumab emtansine

As the list published 23 Sept 2026 has it, binding since 19 Apr 2023. Each entry binds six months after its own publication date (Article 107c(7) of Directive 2001/83/EC).

What the list says

EU reference date
15 Nov 2013
PSUR frequency
2 years
Data lock point
21 Feb 2026
Submission date
22 May 2026
Next data lock point
Not stated
Next submission date
Not stated
Products covered
Centrally authorised (CAP)

Are PSURs required for products referred to in Articles 10(1), 10a and 16a of Directive 2001/83/EC?

No — the list does not require PSURs for these products.

The list asks this as one question for Articles 10(1), 10a and 16a together, and does not answer it for Article 14 at all. A PSUR may in any case be required at the request of a competent authority or as a condition of the marketing authorisation.

Notes in the list

PSUR frequency and DLP were updated on 19/10/2022 DLP was updated on 20/10/2021 PRAC representative was updated on 31/03/2021 DLP was updated on 21/10/2020 PRAC representative and DLP were updated on 25/09/2019 PRAC Rapporteur name was amended on 03/04/2019 DLP was updated on 26/09/2018 DLP was updated on 17/10/2017 Next DLP was updated on 22/09/2016 Next DLP was updated on 30/09/2015 The DLP was amended on 01/04/2014

Track dates like these for your own products: a sample workspace, read-only, no account needed.

Try the demo

The next three reports

  • Data lock point 21 Feb 2028Submission by 21 May 2028
  • Data lock point 21 Feb 2030Submission by 22 May 2030
  • Data lock point 21 Feb 2032Submission by 21 May 2032

Counted from the data lock point the list gives, on the cycle it states: the submission date is 90 days after the data lock point — 70 days for a cycle of twelve months or less, 90 days for a longer one, as GVP Module VII sets out.

In earlier versions of the list

  • EMA/630645/2012 Rev.164 · published 23 Sept 2026

    trastuzumab emtansine — every 2 years, data lock point 21 Feb 2026

  • EMA/630645/2012 Rev.156 · published 4 Feb 2026

    trastuzumab emtansine — every 2 years, data lock point 21 Feb 2026

Source: European Medicines Agency, list of EU reference dates and frequency of submission of periodic safety update reports, EMA/630645/2012 Rev.164, published 23 Sept 2026. Open the published file

Kreastel is a planning and oversight aid for pharmacovigilance obligations. It tracks dates like these for a marketing authorisation holder's own products.

Report a discrepancy — if this page and the published file disagree, the file is right and we want to know.

Kreastel